Persistence of human parvovirus B19 in human tissues

Pathologie Biologie

Volumn 50, Issue 5, 2002, Pages 307-316

  Söderlund Venermo, Maria ^a,b   Hokynar, Kati ^a   Nieminen, Janne ^a   Rautakorpi, Henna ^a   Hedman, Klaus ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Chronic infection; Disease association; DNA persistence; Erythrovirus B19; Polymerase chain reaction (PCR)

Indexed keywords

VIRUS DNA;

ANEMIA; ARTHROPATHY; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW DEPRESSION; CLINICAL FEATURE; DISEASE COURSE; DNA DETERMINATION; FETUS DEATH; HUMAN; PARVOVIRUS; PERSISTENT VIRUS INFECTION; RASH; RHEUMATOID ARTHRITIS; VIREMIA; VIRUS STRAIN;

EID: 0036084861     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0369-8114(02)00307-3     Document Type: Article

References (100)

1. Parvoviral infections and hypoplastic crisis in sickle-cell anaemia
2. Clinical manifestations of human parvovirus B19 in adults
3. Human parvovirus infection in early rheumatoid and inflammatory arthritis
4. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
5. Rheumatologic manifestations of human parvovirus B19 infection in adults
6. Chronic bone marrow failure due to persistent B19 parvovirus infection
7. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy
8. Novel human eryhtrovirus associated with transient aplastic anemia
9. A new parvovirus B19 variant persistent in skin
10. Erythrocyte P antigen: Cellular receptor for B19 parvovirus
11. Multiple glycosphingolipids determine the tissue tropism of parvovirus B19
12. Severe aplastic anaemia after parvovirus infection in the absence of underlying haemolytic anaemia
13. B19 parvovirus-induced anemia in a normal child. Initial bone marrow erythroid hyperplasia and response to intravenous immunoglobulin
14. Human parvovirus infection revealing hereditary spherocytosis
15. Six cases of hereditary spherocytosis revealed by human parvovirus infection
16. Parvovirus B19 and chronic arthritis - Causal or casual association?
17. Human parvovirus B19 infection and juvenile chronic polyarthritis
18. Prevalence of antihuman parvovirus B19 IgG antibodies in patients with refractory rheumatoid arthritis and polyarticular juvenile rheumatoid arthritis
19. Human parvovirus arthropathy and rheumatoid factor
20. HLA acute arthritis following human parvovirus infection
21. Persistent arthritis after human parvovirus B19 infection
22. HLA antigens in human parvovirus arthropathy
23. Influence of previous exposure to human parvovirus B19 infection in explaining susceptibility to rheumatoid arthritis: An analysis of disease discordant twin pairs
24. Human parvovirus B19 in synovial fluid
25. Persistence of parvovirus B19 in synovial fluid and bone marrow
26. Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis
27. A study of the role of parvovirus B19 in rheumatoid arthritis
28. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy
29. Presence and significance of human parvovirus B19 DNA in synovial membranes and bone marrow from patients with arthritis of unknown origin
30. Parvovirus B19 and the pathogenesis of rheumatoid arthritis: A case for historical reasoning
31. Induction of an invasive phenotype by human parvovirus B19 in normal human synovial fibroblasts
32. Rheumatoid arthritis after parvovirus B19 infection
33. Low frequency of recent parvovirus infection in a population-based cohort of patients with early inflammatory polyarthritis
34. Human parvovirus B19 infection is not followed by inflammatory joint disease during long term follow-up. A retrospective study of 54 patients
35. Human parvovirus B19 and rheumatoid arthritis
36. Chronic parvovirus B19 infection and systemic necrotising vasculitis: Opportunistic infection or aetiological agent?
37. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression
38. Autoantibodies following parvovirus B19 infection
39. Autoantibodies and common viral illnesses
40. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties
41. 2 is required for parvovirus infectivity
42. Virus-related arthritis, excluding human immunodeficiency virus
43. Persistent parvovirus B19 infections in immunocompromised children
44. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia
45. Persistent B19 infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia
46. Chronic parvovirus infection in a presumably immunologically healthy woman
47. Parvovirus B19-specific DNA in bone marrow from B19 arthropathy patients: Evidence for B19 virus persistence
48. Persistent infection of human parvovirus B19 in a normal subject
49. Clinical and laboratory findings in immunocompetent patients with persistent parvovirus B19 DNA in bone marrow
50. Parvovirus B19 infection of bone marrow in systemic sclerosis patients
51. Evidence for persistence of human parvovirus B19 DNA in bone marrow
52. Evidence for persistence of parvovirus B19 DNA in livers of adults
53. Accurate serodiagnosis of B19 parvovirus infections by measurement of IgG avidity
54. Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19
55. Integrity and full coding sequence of B19 virus DNA persisting in human synovial tissue
56. High incidence of parvovirus B19 DNA in synovial tissue of patients with undifferentiated mono- and oligoarthritis
57. Human parvovirus B19 as a causative agent for rheumatoid arthritis
58. Parvovirus B19 in the synovium of patients with early synovitis
59. Detection of multiple viral DNA species in synovial tissue and fluid of patients with early arthritis
60. Microbial DNA in the synovium - A role in aetiology or a mere bystander?
61. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis
62. Rubella virus and chronic joint disease: Is there an association?
63. Detection of rubella, mumps, and measles virus genomic RNA in cells from synovial fluid and peripheral blood in early rheumatoid arthritis
64. Chlamydia pneumoniae in atherosclerosis
65. The disease spectrum of Helicobacter pylori: The immunopathogenesis of gastroduodenal ulcer and gastric cancer
66. Detection of Chlamydia trachomatis DNA in joints of reactive arthritis patients by polymerase chain reaction
67. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with lyme arthritis
68. Identification of Mycoplasma fermentas in synovial fluid samples from arthritis patients with inflammatory disease
69. Detection of parvovirus B19 in a skin biopsy of a patient with erythema infectiosum
70. Presence of parvovirus B19 DNA in chronic urticaric and healthy human skin
71. Parvovirus B19 DNA in kidney tissue of patients with focal segmental glomerulosclerosis
72. Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle
73. Persistence of parvovirus B19 DNA in testis of patients with testicular germ cell tumours
74. Parvovirus B19 is associated with benign testes as well as testicular germ cell tumours
75. Biology and pathogenicity of autonomous parvoviruses
76. Antineoplasic activity of parvoviruses
77. IgG subclass response to human parvovirus B19 infection
78. Impaired gamma interferon responses against parvovirus B19 by recently infected children
79. Immune response to B19 parvovirus and an antibody defect in persistent viral infection
80. Lymphoproliferative responses after infection with human parvovirus B19
81. Direct ex vivo measurement of CD8+ T-lymphocyte responses to human parvovirus B19
82. T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus B19
83. Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: Implications for pathogenesis
84. Antibodies to parvovirus B19 nonstructural protein are associated with chronic but not acute arthritis following B19 infection
85. Seroprevalence of parvovirus B19 NS1-specific IgG in B19-infected and uninfected individuals and in infected pregnant women
86. Development of antibodies to the nonstructural protein NS1 of parvovirus B19 during acute symptomatic and subclinical infection in pregnancy
87. IgG response to the immunoreactive region of parvovirus B19 nonstructural protein by immunoblot assay with a recombinant antigen
88. Prevalence of antibodies to human parvovirus B19 nonstructural protein in persons with various clinical outcomes following B19 infection
89. Baculovirus expression of parvovirus B19 (B19V) NS1: Utility in confirming recent infection
90. Partial nucleotide sequencing and characterization of human parvovirus B19 genome DNAs from damaged human fetuses and from patients with leukemia
91. Extent of sequence variability in a genomic region coding for capsid proteins of B19 parvovirus
92. Sequence variability among different parvovirus B19 isolates
93. Genetic diversity of human parvovirus B19: Sequence analysis of the VP1/VP2 gene from multiple isolates
94. Persistent parvovirus infection
95. Variant and defective interfering parvoviruses
96. Ebola virus defective interfering particles and persistent infection
97. A defective interference-like phenomenon of human hepatitis B virus in chronic carriers
98. Site-specific integration by adeno-associated virus
99. The rodent parvoviruses
100. Aleutian mink disease: Puzzles and paradigms